Abbonarsi

Can EUS-guided FNA distinguish between gallbladder cancer and xanthogranulomatous cholecystitis? - 24/08/11

Doi : 10.1016/j.gie.2010.05.022 
Susumu Hijioka, MD , Mohamed A. Mekky, MD, Vikram Bhatia, MD, Akira Sawaki, MD, Nobumasa Mizuno, MD, Kazuo Hara, MD, Waki Hosoda, MD, Yasuhiro Shimizu, MD, Kiichi Tamada, MD, Yasumasa Niwa, MD, Kenji Yamao, MD
Current affiliations: Department of Gastroenterology (S.H., A.S., N.M., K.H., K.Y.), Department of Pathology and Molecular Diagnostics (W.H.), Department of Surgery (Y.S.), Department of Endoscopy (Y.N.), Aichi Cancer Center Hospital, Nagoya, Japan; Department of Tropical Medicine and Gastroenterology (M.A.M.), Assiut University Hospital, Assiut, Egypt; Department of Medical Hepatology (V.B.), Institute of Liver and Biliary Sciences, Delhi, India; Department of Gastroenterology (K.T.), Jichi Medical University, Tochigi, Japan 

Reprint requests: Susumu Hijioka, MD, Department of Gastroenterology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan

Riassunto

Background

EUS-guided FNA (EUS-FNA) is a useful modality for sampling various targets, but its applicability to gallbladder (GB) mass lesions is limited.

Objective

To determine the usefulness of EUS-FNA for diagnosing GB mass lesions.

Design

Single-center, retrospective, case-series study.

Setting

Tertiary-care referral center.

Patients

This study involved 15 consecutive patients who underwent EUS-FNA of GB mass lesions. We punctured GB masses in patients with suspected xanthogranulomatous cholecystitis to distinguish them from malignancy, and in patients with unresectable GB carcinoma for pathological confirmation. The final diagnosis was based on surgical histopathological results or follow-up outcome.

Interventions

EUS-FNA.

Main Outcome Measurements

Evaluation of EUS-FNA sampling adequacy rate and diagnostic yield.

Results

Xanthogranulomatous cholecystitis was suspected in 6 of the 15 patients. EUS-FNA revealed foam cells (n = 3), inflammatory cells (n = 1, proven by cholecystectomy), and GB carcinoma (n = 1), and the amount of the aspirate was insufficient in one case (xanthogranulomatous cholecystitis was later proven by extended hepatectomy). The mean follow-up period of the patients with xanthogranulomatous cholecystitis was 1177 days. Adenocarcinoma was confirmed by EUS-FNA in 8 of the 9 patients with suspected unresectable GB carcinoma, and the FNA was inconclusive in one. All 10 patients with GB carcinoma underwent chemotherapy. The overall sampling adequacy was 86.6%. The accuracy of EUS-FNA for detecting malignancy and for the final diagnosis was 93.3% (95% CI, 62.4%-99.9%) and 80% (95% CI, 54%-93.7%), respectively.

Limitations

A small patient cohort and a retrospective design with potential selection bias.

Conclusions

Malignant GB mass lesions can be safely and accurately differentiated by EUS-FNA. Thus, patients with xanthogranulomatous cholecystitis can avoid undue extensive surgery.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : EUS-FNA, GB, LN, XGC


Mappa


 DISCLOSURE: All authors disclosed no financial relationships relevant to this publication.


© 2010  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 72 - N° 3

P. 622-627 - settembre 2010 Ritorno al numero
Articolo precedente Articolo precedente
  • Gone but not forgotten. “Bubble gum enema” containing hydrogen peroxide and causing life-threatening colitis
  • Rizwan Kibria, Syed A. Ali, Christopher J. Barde
| Articolo seguente Articolo seguente
  • Large-diameter therapeutic channel duodenoscope to facilitate simultaneous deployment of side-by-side self-expandable metal stents in hilar cholangiocarcinoma
  • Atif Saleem, Todd H. Baron, Christopher J. Gostout

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.